Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The immune checkpoint inhibitors have brought about a paradigm shift in the treatment of many cancers and are being used as the first line therapy in increasing number of aggressive malignancies, including metastatic melanoma. Their adverse effects, mostly mediated by an uncontrolled overactivation of the immune system, may compromise the therapeutic benefit. Combination immune checkpoint therapies in particular, have higher therapeutic efficacy, but have also been associated with a higher incidence of severe immune-related adverse effects including autoimmune lymphocytic myocarditis. Recent clinical reports of this rare and life threatening condition indicated rapid progression of severe hemodynamic and electrical instability, with or without acute decompensated heart failure, reduced ejection fraction and shock, pointing to the need for early recognition, diagnosis and prompt management. Current guidelines for management of other immune-related adverse effects recommend high-dose glucocorticoids, with consideration of immunomodulators, such as infliximab in patients with severe colitis. However, knowledge about the treatment approaches in immune-related myocarditis remains extremely scarce. Here we report a case of severe, steroid refractory, lymphocytic myocarditis that occurred after the first cycle of combination immunotherapy with the programmed cell death protein-1 inhibitor, nivolumab, and the cytotoxic T-lymphocyte-associated protein 4 blocker, ipilimumab, for metastatic melanoma. We discuss treatment approaches including the role for transvenous pacemaker, advanced heart failure support, and interdisciplinary decision making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In cases refractory to steroids, other immunomodulators, including abatacept (a CTLA-4 agonist), alemtuzumab (anti-CD52 antibody), and antithymocyte globulin (antiCD3 antibody) have been used in case reports.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [262]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper
Friedrich, M. G., Sechtem, U., Schulz-Menger, J., Holmvang, G., Alakija, P., Cooper, L. T., White, J. A., Abdel-Aty, H., Gutberlet, M., Prasad, S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.007 · Cited by 2,509
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200
Cited by
Ammirati, E., Frigerio, M., Adler, E. D., Basso, C., Birnie, D. H., Brambatti, M., Friedrich, M. G., Klingel, K., Lehtonen, J., Moslehi, J. J., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007405 · Cited by 811
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 291
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy
Michel, L., Helfrich, I., Hendgen-Cotta, U. B., Mincu, R.-I., Korste, S., Mrotzek, S. M., Spomer, A., Odersky, A., Rischpler, C., Herrmann, K., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab430 · Cited by 168
Ammirati, E., Veronese, G., Bottiroli, M., Wang, D. W., Cipriani, M., Garascia, A., Pedrotti, P., ADLER, E. D., & Frigerio, M. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.05.008 · Cited by 172
Cardiotoxicity of Immune Checkpoint Inhibitors
Patel, R. P., Parikh, R., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 152
Metadata
- Authors
- Jain, V., Mohebtash, M., Rodrigo, M. E., Ruiz, G., Atkins, M. B., & Barac, A.
- Affiliations
- Georgetown University (US)
- MedStar Union Memorial Hospital (US)
- Corresponding author
- Jain, Varun
- Rodrigo, Maria E.
- Barac, Ana
- Venue
- Journal of Immunotherapy
- Published
- 2018-09
- Volume
- 41
- Issue
- 7
- Pages
- 332-335
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2810244089
- Semantic Scholar
- 73d6d6ab68f382c082fe79fd6ddfec835bf7de95
- Cited by
- 96
- References
- 12
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 9 · 2023: 8 · 2022: 16 · 2021: 15 · 2020: 19 · 2019: 12 · 2018: 3
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- autoimmune myocarditis, immune checkpoint inhibitors, antithymocyte globulin, nivolumab, ipilimumab, immune-related adverse events, metastatic melanoma, combination immunotherapy, heart failure, transvenous pacemaker, immunomodulatory therapy
- MeSH terms
- Ipilimumab, Nivolumab, Aged, Antilymphocyte Serum, Autoimmune Diseases, Drug Resistance, Drug Therapy, Combination, Glucocorticoids, Humans, Immunotherapy, Male, Melanoma, Myocarditis, Neoplasm Metastasis, Skin Neoplasms, Treatment Outcome, Programmed Cell Death 1 Receptor, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. https://app.cochat.ai/papers/10.1097/cji.0000000000000239
- The paper
- Jain, V., Mohebtash, M., Rodrigo, M. E., Ruiz, G., Atkins, M. B., & Barac, A. (2018). Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. Journal of Immunotherapy. https://doi.org/10.1097/cji.0000000000000239
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.